Meeting
2016 Gastrointestinal Cancers Symposium
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for stage III colon cancer patients who underwent curative resection (KSCC1303).
Authors
Nobutomo Miyanari
National Hosptal Organization Kumamoto Medlical Center, Kumamoto, Japan
Nobutomo Miyanari , Yasunori Emi , Akihito Tsuji , Kenji Sakai , Hideaki Anai , Hiroaki Takeshita , Hiroshi Imamura , Shinichiro Mori , Takayuki Shimose , Eiji Oki , Hiroshi Saeki , Yoshihiro Kakeji , Yoshito Akagi , Hideo Baba , Yoshihiko Maehara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000012618
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 739)
DOI
10.1200/jco.2016.34.4_suppl.739
Abstract #
739
Poster Bd #
M14
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
“Real world” effectiveness of different postoperative adjuvant chemotherapy regimens in stage III colon cancer patients.
First Author: Jy Ming Chiang
Poster
2016 Gastrointestinal Cancers Symposium
Impact of relative dose intensity and G-CSF use in the adjuvant treatment of resected colon cancer.
First Author: Daniel Adam Breadner
Poster
2022 ASCO Annual Meeting
A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.
First Author: Yu Pengfei
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration.
First Author: Daniel Walden